Analyst Ratings for Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received a total of 10 analyst ratings in the last quarter, with 6 being bullish, 2 somewhat bullish, and 2 indifferent. The average price target is $113.5, representing an upside from the current price of $70.5. This average price target is a 2.85% decrease from the previous average price target of $116.83.
August 11, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received mostly bullish analyst ratings in the last quarter, with an average price target indicating an upside from the current price.
The majority of the analyst ratings for Axsome Therapeutics in the last quarter have been bullish, indicating a positive outlook for the stock. The average price target also suggests an upside from the current price, which could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100